Fuad El-Hibri Blog

December 16, 2009

Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young

Marie-José Daoud

Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which will be awarded on November 14 in California
He is a tall, imposing and smiling man. He has the assurance of those who are proud of their career and the modesty of those who attribute their success to the staff around them. He has just won the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region. This prize rewards over 15 years in the biopharmaceutical industry, ten of which have been dedicated to Emergent Biosolutions, the company that supplies the only anthrax vaccine approved by the American government’s powerful Food and Drug Administration (FDA). Fuad El-Hibri landed in biopharmaceuticals somewhat by chance and somewhat by interest. He defines himself as “an entrepreneur in spirit” and, before dedicating himself to biopharmaceuticals, he had already created and sold various telecommunications companies in Russia, Venezuela and El Salvador. In the early 90s, this German native, born to a Lebanese father and a German mother, and who had spent time in the banking industry (Citibank) and consultant (BoozAllen & Hamilton), joins Porton Product, a biotechnology company located in the United Kingdom. There he plays a predominant role in marketing and sales of biodefense vaccines to foreign governments. Hibri is, in particular, a key man behind the purchase by Saudi Arabia of anthrax vaccines during the first Gulf war. This is where he maintains he gained his insight into the magnitude of the need for medical solutions to combat bioterrorism. In 1994, he organized the buy-back of Porton Products by its managers, before reselling his shares in 1996 (the price is not known).

In 1998, an opportunity opened up for him to buy BioThrax in competitive bidding, the only anti-anthrax vaccine approved by the Food and Drug Administration, until then owned by the State of Michigan. So he creates BioPort, obtains American nationality . in 1999, wins the bidding (approximately 24 million dollars) and finds himself at the head of a company with 170 employees, and develops a product: BioThrax.

Hibri has in fact the advantage of a monopoly situation since he is the only supplier of the American government who buys millions of doses of BioThrax per year from him to vaccinate its servicemen and to maintain a stock in case of bioterrorist attack. A situation which fuels all the controversies, as proved by the frenzied comments posted on the Internet.

Once BioPort is consolidated, and to diversify his portfolio, Hibri buys several biotechnology companies. In 2003, BioPort buys Antex, an American company working on the development of a vaccine against chlamydia. In 2005, the company, which in the meantime has become Emergent Biosolutions, acquired Microscience, an English company which had invested in research on hepatitis B and typhoid. In 2006, it purchased VIVACS, a German company specialized in research on the influenza vaccine. In 2008, it does a joint venture with Oxford University (among others) to develop a vaccine against tuberculosis.

Today, Emergent is at the head of a developing portfolio of vaccines and treatments against seven diseases which could bring in “hundreds of millions of dollars per year” when the products are on the market, according to Hibri. Four of these should be on the market within four to seven years. Most of these products have the specific feature of only requiring two technologies that the company has: a technology for vaccines given orally and another for vaccines administered by injection. “Which leads to major synergies enabling substantial cost savings to be made,” explains Hibri. But Emergent is in direct competition with large pharmaceutical laboratories such as Sanofi, Novartis and Roche on the development of these treatments and vaccines, of more commercial use than BioThrax. Furthermore, even with anthrax, Emergent will probably have to face competition from other biotechnology laboratories, like PharmAthene and Cangene, who are currently in the development phase of vaccines and treatment against the bacterium. In the meantime, to meet increasing demand from the American government, and that of other foreign governments who fill out its client portfolio, Emergent has recently invested in its BioThrax production capacity: it has gone from a capacity of three million doses per year to eight million and is currently validating a new factory in Michigan which can produce up to 40 million doses per year.

Today, eleven years after acquiring BioThrax, the latter, still provides the bulk of the company’s turnover (178.6 million dollars in 2008), the other part coming from development contracts with the government and revenue granted by public or private funds.

Anthrax

Anthrax is an infectious disease caused by the spore-forming bacterium Bacillus anthracis.

Anthrax most commonly occurs in wild and domestic animals but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

The disease is transmitted by spores, or contaminated hide, but not from human to human. Cultivation of the bacterium and spores are relatively easy in a laboratory, which makes it an ideal biological weapon.

The company has 600 employees and has been quoted on the New York stock exchange since 2006, with a capitalization of 500 million dollars. Hibri, his family and his management staff keep control of the company with over half of the capital. Emergent has a presence in the United States, United Kingdom, Singapore, China and Germany. And for seven years, between 2000 and 2007, it has experienced uninterrupted growth.

This is partially why the E&Y prize was awarded to Hibri. Other criteria were also taken into account: his ability to inspire his staff, who, he himself acknowledges are “dedicated and motivated”; and his philanthropic involvement in numerous charity organizations, among which the El-Hibri Charitable Foundation, created by his father, that among other things finances the Dar Al-Aytam orphanage in Lebanon.

www.emergentbiosolutions.com

June 15, 2009

Fuad El-Hibri’s Emergent BioSolutions’ Typhoid Vaccine

Fuad El-Hibri’s Emergent BioSolutionsTyphoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study

“We are very pleased to have met the objectives of this Phase II study of our typhoid vaccine candidate. This data is encouraging and indicates great promise for what would be the first single-dose, drinkable typhoid vaccine. We are particularly grateful to the Wellcome Trust for their partnership and generous support of this important project,” stated Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “Typhoid is endemic in many developing countries, putting countless international travelers and families who visit these nations at risk. With typhoid claiming 200,000 lives each year, continued progress in the development of this vaccine is an important milestone in our company’s efforts to protect life. Emergent BioSolutions remains committed to addressing significant underserved health needs,” he continued.

About the Typhoid Vaccine Candidate

The company’s typhoid vaccine candidate is a live, attenuated strain of the Salmonella typhi bacterium designed to eliminate virulence by deletion of two specific genes. The vaccine is intended to be administered in a single, drinkable dose prior to travel to countries where typhoid is endemic. If approved, this method of administration could provide a competitive advantage compared to currently approved typhoid vaccines.

Reblog this post [with Zemanta]

June 14, 2009

Fuad El-Hibri on The Alacra Store Newstex

Fuad El-Hibri on The Alacra Store Newstex

Report title: Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington

May 8, 2009 (Business Wire) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year« 2009 Award in the…

Source: Business Wire
Company: EMERGENT BIOSOLUTIONS INC.
Event(s): Events, Events and Awards
Category(ies): economy, business and finance
Ticker: EBS
Exchange: NYSE
Free Sample: Click Here to Download

Reblog this post [with Zemanta]

Fuad El-Hibri on Highbeam

Fuad El-Hibri on Highbeam

Article: Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington.

ROCKVILLE, Md. — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year([R]) 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in …

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Biotech Week Article: Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named…

Newspaper article from: Biotech Week ;  May 27, 2009 ; 519 words … Emergent BioSolutions Inc. (NYSE…the Ernst & Young Entrepreneur of the Year…Virginia (see also Emergent BioSolutions Inc.). It is…the Ernst & Young Entrepreneur of the Year…the Ernst & Young Entrepreneur of the Year…Keywords: Emergent

PR Newswire Europe Article: Emergent BioSolutions Expands Presence in Germany.

Press release article from: PR Newswire Europe ;  August 3, 2006 ; 411 words …Technology Platform (MVAtor(TM)) Emergent BioSolutions Inc., a privately held biopharmaceutical…transaction were not disclosed. Emergent BioSolutions, which has an existing sales and…currently serves as President of Emergent BioSolutions‘ sales and marketing subsidiary…

PR Newswire Article: Emergent BioSolutions Signs Agreement With sanofi pasteur for…

Press release article from: PR Newswire ;  June 5, 2006 ; 700+ words …pasteur Receives Exclusive Rights to Emergent BioSolutions‘ Technology; Emergent BioSolutions to Lead Early Development and Receive…GAITHERSBURG, Md., June 5 /PRNewswire/ — Emergent BioSolutions Inc, a privately-held biopharmaceutical…

PR Newswire Article: Emergent BioSolutions Sponsors Phacilitate Vaccine Forum 2006.

Press release article from: PR Newswire ;  January 26, 2006 ; 233 words …GAITHERSBURG, Md., Jan. 26 /PRNewswire/ — Emergent BioSolutions Inc. announced today that it is the…viral vaccines for unmet needs. About Emergent BioSolutions Inc. Emergent BioSolutions Inc. is dedicated to the research…

PR Newswire Article: Emergent BioSolutions Appoints Allen Shofe Vice President of…

Press release article from: PR Newswire ;  September 15, 2005 ; 359 words …Md., Sept. 15 /PRNewswire/ — Emergent BioSolutions Inc. today announced the appointment…executive, said Fuad El-Hibri, CEO of Emergent BioSolutions. His government affairs expertise…the opportunity to help advance Emergent BioSolutions into a world class biopharmaceutical…

PR Newswire Article: Emergent BioSolutions to Present at 24th Annual JP Morgan…

Press release article from: PR Newswire ;  January 5, 2006 ; 188 words … GAITHERSBURG, Md., Jan. 5 /PRNewswire/ — Emergent BioSolutions Inc. announced today that it will…opportunities for the company. About Emergent BioSolutions Inc. Emergent BioSolutions Inc. is dedicated to the research…

Business Wire Article: Emergent BioSolutions to Present at the Cowen & Company 27th…

Press release article from: Business Wire ;  March 5, 2007 ; 245 words … ROCKVILLE, Md. — Emergent BioSolutions Inc. (NYSE:EBS) announced…chief executive officer of Emergent BioSolutions and Dr. Stephen N. Chatfield…chief scientific officer of Emergent BioSolutions, will provide a company…

M2 Presswire Article: Analysis of Emergent BioSolutions, Inc.

Press release article from: M2 Presswire ;  January 8, 2007 ; 700+ words …ESSWIRE-8 January 2007-Biotech News: Analysis of Emergent BioSolutions, Inc.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:08012007 Analysis of Emergent BioSolutions, Inc. (NYSE:EBS) Emergent BioSolutions protects your thorax against anthrax. Emergent

PR Newswire Article: Emergent BioSolutions Announces Appointment of Ronald Richard to…

Press release article from: PR Newswire ;  January 26, 2005 ; 449 words … GAITHERSBURG, Md., Jan. 26 /PRNewswire/ — Emergent BioSolutions Inc., today announced the appointment…and Chief Executive Officer of Emergent BioSolutions. We believe that his extensive…Cambridge Universities). About Emergent BioSolutions Inc. Emergent BioSolutions

M2 Presswire Article: Emergent BioSolutions Inc. Under Current Review.

Press release article from: M2 Presswire ;  March 9, 2007 ; 700+ words …March 2007-www.streetinvesting.com: Emergent BioSolutions Inc. Under Current Review(C)1994-20…heavy selling pace. Shareholders of Emergent BioSolutions Inc. (NYSE:EBS) were able to cash…throughout the American Markets. Emergent BioSolutions Inc. was one of the prospective…

PR Newswire Article: Dr. Shahzad Malik Named to Board of Directors of Emergent…

Press release article from: PR Newswire ;  July 13, 2005 ; 382 words … GAITHERSBURG, Md., July 13 /PRNewswire/ — Emergent BioSolutions announced today that Dr. Shahzad…infectious diseases, stated Dr. Malik. Emergent BioSolutions is well positioned to succeed in…achieving those important goals. About Emergent BioSolutions Inc. Emergent

PR Newswire Article: Emergent BioSolutions Awarded Two Grants From NIAID to Support…

Press release article from: PR Newswire ;  August 31, 2006 ; 508 words …GAITHERSBURG, Md., Aug. 31 /PRNewswire/ — Emergent BioSolutions Inc., a privately held biopharmaceutical…Implementation Cooperative Agreement. Emergent BioSolutions‘ AIG Program The company’s AIG…commercial production batches. About Emergent BioSolutions Inc. Emergent

M2 Presswire Article: Current Research on Emergent BioSolutions, Inc.

Press release article from: M2 Presswire ;  June 21, 2007 ; 700+ words …2007-Biotech News: Current Research on Emergent BioSolutions, Inc.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:21062007 Emergent BioSolutions protects your thorax against anthrax. Emergent BioSolutions develops and produces, for the US government…

PR Newswire Europe Article: Emergent BioSolutions Inc. Files Registration Statement for…

Press release article from: PR Newswire Europe ;  August 15, 2006 ; 303 words …Maryland, August 15 /PRNewswire/ — Emergent BioSolutions Inc. announced today that it has…the co-manager for the offering. Emergent BioSolutions is a biopharmaceutical company…commercial. In its biodefense business, Emergent BioSolutions develops and commercializes …

Business Wire Article: Emergent BioSolutions Announces Appointment of Dr. Steven…

Press release article from: Business Wire ;  January 10, 2005 ; 459 words … GAITHERSBURG, Md. — Emergent BioSolutions Inc., today announced…Executive Officer of Emergent BioSolutions. Steve has demonstrated…research and development. Emergent BioSolutions is a unique company…

Reblog this post [with Zemanta]

Fuad El-Hibri on EvaluatePharma

Fuad El-Hibri on EvaluatePharma

Headline Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington
Source Press Release
Company Emergent BioSolutions
Date May 08, 2009
Rockville, MD – May 8, 2009 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year® 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award,” said Mr. Fuad El-Hibri. “I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company’s success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life.”

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

About Ernst & Young’s Entrepreneur of the Year® Awards Program

Ernst & Young’s Entrepreneur of the Year® Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year® award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Reblog this post [with Zemanta]

Fuad El-Hibri Sample Business Contracts

Fuad El-Hibri Sample Business Contracts

Fuad El-Hibri
August 9, 2006
Dear Fuad:
After careful consideration, Emergent BioSolutions Inc. (the “Company”) has decided to implement a Severance and Termination Protection Program (the “Program”) to recognize the valuable services that certain employees have provided, and will continue to provide, to the Company and its affiliates. You are eligible to participate in the Program, provided that you make the agreements and acknowledgements set forth below, including that (1) all offer letters and employment agreements between you and the Company (and/or its affiliates), including any amendments, are terminated and (2) you will comply with the terms and conditions set forth in Exhibit I hereto, as amended. Any indemnification agreement, stock option agreement, shareholder agreement, confidentiality obligations, and invention assignment agreements that you may have with the Company or its affiliates are not affected by this letter or by your participation in the Program and remain in full force and effect.
You have received a summary of the Program and a full copy of the Program itself. Please review the Program details carefully. If you elect to become a participant in the Program, please sign below and return the signed copy to Paula Lazarich, Vice President, Human Resources, no later than Friday, August 11, 2006. Please contact Paula at 301-944-0180 or me at 301-944-0107 if you have any questions.
Sincerely,
/s/ Daniel Abdun-Nabi
Daniel Abdun-Nabi
Senior Vice President, Corporate Affairs
General Counsel
As of the date set forth below, I acknowledge and agree that:
(1) I am electing to become a participant in, and to be subject to the terms and conditions of, the Program; and
(2) All offer letters and employment agreements between the Company and/or its affiliates and me are hereby terminated, and, as a result:
a. I have no employment contract (oral or written) with the Company or its affiliates governing the terms and conditions of my employment;
b. I am an at-will employee, and my employer or I may terminate my employment at any time for any reason or for no reason;
c. My compensation is not governed by an employment agreement with the Company or its affiliates but, instead, is governed by my employer’s general benefit plans, as they may be amended from time to time, unless the Company notifies me otherwise in writing;
d. the Company and its affiliates have no liability or obligations to me under my terminated employment agreement(s); and
(3) I will comply with the terms and conditions of Exhibit I hereto, as amended, including the non-compete and non-solicitation provisions.
/s/ Fuad El-Hibri 8/9/06
Fuad El-Hibri Dated

Mr. El-Hibri
August 9, 2006
Page 2
(EMERGENT LOGO)
EXHIBIT I
(1) Nonsolicitation; Noncompete. I agree that, during my employment by the Company or any Affiliate (each as defined in the Program) and for a period of eighteen (18) consecutive months after my employment ceases for any reason, I shall not, directly or indirectly,
(i) either alone or in association with others, (A) induce, counsel, advise, solicit or encourage, or attempt to induce, counsel, advise, solicit or encourage any employee to leave the employ of the Company, or any of its Affiliates, or accept employment with any other person or entity, (B) induce counsel, advise, solicit or encourage, or attempt to induce, counsel, advise, solicit or encourage any person who at the time of such inducement, counseling, advice, solicitation or encouragement had left the employ of the Company, or any of its Affiliates, within the previous six (6) months to accept employment with any person or entity besides the Company, or any of its Affiliates, or hire or engage such person as an independent contractor, or (C) solicit, interfere with, or endeavor to cause any customer, client, or business partner of the Company, or any of its Affiliates, to cease or reduce its relationship with the Company, or any of its Affiliates, or induce or attempt to induce any such customer, client, or business partner to breach any agreement that such customer, client, or business partner may have with the Company, or any of its Affiliates; and
(ii) whether or not for compensation, and whether or not as an employee, be engaged in or have a financial interest in any business, competing with the business of the Company or of any Affiliate within any state, region or locality in which the Company or such Affiliate is then doing business or marketing products, as the business of the Company or such Affiliates may then be constituted. With respect to this sub-section, however, it is understood and agreed that a business is not competing with the business of the Company or any Affiliate if (A) my duties with respect to such business relate solely to discrete business units that do not compete with the business of the Company or any Affiliate; or (B) the competitive activity is limited to geographical markets or products in which the Company or Affiliate was not engaged (whether by manufacture, distribution, sale, or development for manufacture, distribution, or sale) during the two (2) years immediately preceding my ceasing to be employed by the Company.
(2) Miscellaneous. (i) If any restriction in this Exhibit is found by a court of competent jurisdiction to be unenforceable because it extends for too long a period or covers too great a range of activities or in too broad a geographic area, it shall be interpreted to be effective to the extent it is enforceable. The invalidity or unenforceability of any provision shall not affect the validity or enforceability of any other provision of this Exhibit.
(ii) I acknowledge the restrictions contained in this Exhibit are reasonable and necessary for the protection of the business and goodwill of the Company. I agree that any breach or threatened breach of this Exhibit will cause the Company substantial and irrevocable damage that is difficult to measure and that a remedy at law is not adequate. In the event of breach or threatened breach, I agree that the Company, in addition to other available remedies, shall have the right to seek specific performance and injunctive relief without posting a bond.
(iii) This Exhibit supersedes all prior agreements, written or oral, between the Company and me relating to the subject matter of Section 1, including any provisions in the Program, and shall apply irrespective of the reason my employment ends.

Mr. El-Hibri
August 9, 2006
Page 3
(EMERGENT LOGO)
(v) No delay or omission by the Company in exercising any right under this Exhibit will operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.
(vi) This Exhibit shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation or entity with which or into which the Company may be merged or that may succeed to all or substantially all of its assets or business.
(vii) This Exhibit may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Company and me. This Exhibit shall be governed by and construed as a sealed instrument under and in accordance with the laws of the State of Delaware without regard to conflicts of law provisions.

Mr. El-Hibri
August 9, 2006
Page 4
(EMERGENT LOGO)
Amendment to Exhibit I
Notwithstanding anything to the contrary in Exhibit I to the August 9, 2006 Letter from Emergent BioSolutions Inc. (the “Company”) to Fuad El-Hibri, Mr. El-Hibri and the Company hereby acknowledge and agree as follows:
1. The Company acknowledges that Mr. El-Hibri is a member of the board of trustees of American University, a member of the board of directors of the International BioMedical Research Alliance, and director and treasurer of the El-Hibri Charitable Foundation; that Mr. El-Hibri also serves as a director and/or officer of Digicel Holdings, Ltd., Telectronics, Inc., East West Resources Corporation, Intervac LLC, and Intervac Management LLC; and that Mr. El-Hibri manages certain of his own personal investments, including real estate holding companies. The Company agrees that Mr. El-Hibri’s service in such capacities has not interfered with his ability to perform his duties to the Company and, assuming continued service in such capacities at levels of time and attention comparable to those that Mr. El-Hibri has provided to such entities within the preceding twelve months, would not violate Exhibit I or interfere with Mr. El-Hibri’s ability to perform his duties to the Company.
2. It shall not be a violation of Exhibit I for Mr. El-Hibri to pursue any business transaction or opportunity where such transaction or opportunity was first presented (i) to Mr. El-Hibri in his capacity as an officer or director of the entities identified in Paragraph 1, above or (ii) to the Company, and the Board of Directors of the Company declined to pursue such transaction or opportunity.
3. With respect to Mauro Gibellini, Jose Ochoa, and Kerry Kisling, three employees who, at Mr. El-Hibri’s invitation, left their employment with East West Resources Corporation (EWR) to accept employment with the Company, it shall not be a violation of Exhibit I for Mr. El-Hibri to induce, counsel, advise, solicit or encourage, or attempt to induce, counsel, advise, solicit or encourage those employees to return to employment with EWR.
/s/ Fuad El-Hibri
8/9/06
Fuad El-Hibri
Date
Acknowledged and Agreed:
Emergent BioSolutions Inc.
By:
/s/ Daniel Abdun-Nabi 8/9/06
Name:
Daniel Abdun-Nabi Date
Title:
Senior Vice President, Corporate Affairs

General Counsel

Reblog this post [with Zemanta]

Fuad El-Hibri on BusinessWire

Fuad El-Hibri on BusinessWire

 Emergent BioSolutions Inc.

Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington

ROCKVILLE, Md.–(BUSINESS WIRE)–Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year® 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award,” said Mr. Fuad El-Hibri. “I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company’s success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life.”

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young’s Entrepreneur of the Year® Awards Program

Ernst & Young’s Entrepreneur of the Year® Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year® award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Contacts

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Reblog this post [with Zemanta]

Mr. Fuad El-Hibri on BioSpace

Mr. Fuad El-Hibri on BioSpace

Emergent BioSolutions (EBS) Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young LLP Entrepreneur of the Year 2009 Award Finalist in Greater Washington
5/8/2009

ROCKVILLE, Md.–(BUSINESS WIRE)–Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year® 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

Read at BioSpace.com

Reblog this post [with Zemanta]

Mr. Fuad El-Hibri on Reuters

Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington

ROCKVILLE, Md.–(Business Wire)– Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year® 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award,” said Mr. Fuad El-Hibri. “I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company`s success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life.”

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body`s immune system to prevent or treat disease. Emergent`s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent`s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young`s Entrepreneur of the Year® Awards Program

Ernst & Young`s Entrepreneur of the Year® Award is the world`s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year® award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Copyright Business Wire 2009

Reblog this post [with Zemanta]

Mr. Fuad El-Hibri named Ernst & Young Entrepreneur of the Year 2009 award finalist in greater Washington

Emergent BioSolutions chairman and CEO, Mr. Fuad El-Hibri, named Ernst & Young Entrepreneur of the Year 2009 award finalist in greater Washington

ROCKVILLE, Md. – (BUSINESS WIRE) – Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award,” said Mr. Fuad El-Hibri. “I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company’s success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life.”

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young’s Entrepreneur of the Year Awards Program

Ernst & Young’s Entrepreneur of the Year Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Comment on this story, by email comment@newsblaze.com

Reblog this post [with Zemanta]

Theme: Shocking Blue Green. Blog at WordPress.com.

Follow

Get every new post delivered to your Inbox.